<DOC>
	<DOCNO>NCT02492763</DOCNO>
	<brief_summary>This multicenter randomize , double-blind , placebo- active-controlled ( liraglutide ; Victoza® ) , parallel-group , clinical trial MK-8521 participant type 2 diabetes mellitus ( T2DM ) inadequate glycemic control stable dose metformin ( ≥1000 mg/day ) . The trial include 1-week screening period ; 8-week antihyperglycemic agent ( AHA ) washout period , require ; 14-week blind therapy period ( include single-blind run-in double-blind therapy ) ; 14-day post-treatment visit , 2 week last dose investigational product . The primary hypothesis trial ass hemoglobin A1c ( HbA1C ) -lowering efficacy addition MK-8521 relative placebo evaluate safety tolerability MK-8521 .</brief_summary>
	<brief_title>A Preliminary Study Efficacy Safety MK-8521 Type 2 Diabetes ( MK-8521-004 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Have T2DM accordance American Diabetes Association guideline Be metformin monotherapy ( &gt; 1000 mg/day : metformin IR metformin XR ) least 12 week prior study start hemoglobin A1C ( A1C ) &gt; 7.5 &lt; 10.5 % OR Be dual therapy metformin ( &gt; 1000 mg/day : dose stable least 4 week prior study start ) A1C &gt; 7.0 % &lt; 10.0 % second AHA willing washout second AHA . Allowable AHAs dipeptidyl peptidase 4 ( DPP4 inhibitor ) , alphaglucosidase inhibitor , sulfonylurea , glinides . Have body mass index ( BMI ) ≥23 kg/m2 ≤40 kg/m2 Is female reproductive potential , female reproductive potential agree avoid become pregnant : receiving study drug 14 day last dose study drug Have history type 1 diabetes history diabetic ketoacidosis Has history specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrinopathies , drug chemicalinduced , postorgan transplant ) Has treat gutderived incretin hormone glucagonlike peptide 1 ( GLP1 ) receptor agonist ( e.g . Byetta™ , Victoza™ investigational agent ) within last 6 month GLP1 receptor agonist discontinue due gastrointestinal intolerance lack efficacy . Note : treatment GLP1 receptor agonist discontinue &gt; 6 month prior study start exclusion GLP1 receptor agonist discontinue reason gastrointestinal intolerance lack efficacy . Has history clinically significant gastrointestinal disorder ( include diabetic gastroparesis ; irritable bowel disease ; recurrent episodes nausea , vomit , diarrhea abdominal pain ) Has history clinically significant active , immunological , respiratory , genitourinary major neurological ( include stroke , transient ischemic attack chronic seizure ) abnormality diseases Has history cardiovascular disease ( include diabetic cardiomyopathy ) significant cardiac condition ( include history myocardial infarction , stable unstable angina , arterial revascularization , pathologic , symptomatic sustain tachyarrhythmia [ e.g . atrial fibrillation , sustain supraventricular tachycardia , symptomatic nonsustained supraventricular tachycardia , ventricular tachycardia , ventricular fibrillation , WolfParkinsonWhite syndrome , congenital long QT syndrome , etc . ] ) heart failure Has family history medullary carcinoma thyroid multiple endocrine neoplasm type2 syndrome Has active diabetic proliferative retinopathy history maculopathy Has human immunodeficiency virus ( HIV ) Has medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic hepatitis B C ( assessed medical history ) , primary biliary cirrhosis , active symptomatic gallbladder disease Is weight loss medication undergone bariatric surgery Has history acute chronic pancreatitis etiology Had event severe hypoglycemia neuroglycopenia past 12 month Has positive urine pregnancy test Is pregnant breastfeeding , plan conceive trial , include 14 day follow last dose investigational product Routinely consume &gt; 1 alcoholic drink per day &gt; 7 alcoholic drink per week engages binge drink Routinely consume ≥480mg /day caffeine caffeinated beverage ( 1 cup coffee contain approximately 120 mg caffeine Is take beta blocker medication sympathomimetic activity ( e.g . pseudoephedrine , phenylpropanolamine , etc . ) Is currently user nicotine nicotine containing product agree refrain use nicotine trial , include 14 day follow last dose investigational product Is currently user illicit drug ( include marijuana use ) history drug ( include alcohol ) abuse within approximately 5 year severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation blind investigational product administration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>